Navigation Links
BioLife Solutions Announces Second Quarter 2017 Financial Results

BOTHELL, Wash., Aug. 10, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today reported operational highlights and financial results for the three and six months ended June 30, 2017.

Revenue from biopreservation media product sales reached a new high of $2.6 million in the second quarter of 2017, an increase of 29% over the same period in 2016. This was the eighth consecutive quarter of record revenue. Revenue for the six months ended June 30, 2017 was $4.9 million, or 28% above 2016. Revenue growth for both periods was driven by sales of CryoStor® and HypoThermosol® clinical grade biopreservation media products to the regenerative medicine segment and BioLife's worldwide distributor network.

Mike Rice, BioLife President & CEO, commented, "In the second quarter of 2017, we continued to execute our growth plans as evidenced by our record revenue and operating expense discipline. We are on track for a very successful 2017, as we anticipate continued increased demand from the regenerative medicine segment, customer regulatory approvals and new customers in early phases of cell therapy development."

Q2 2017 Operational Highlights

  • 8th consecutive quarter of record biopreservation media revenue highlighted by the 3rd consecutive quarter with at least $1 million in revenue from the regenerative medicine segment.
  • 28 new direct customers were gained, including initial orders from 11 regenerative medicine companies.
  • Executed a long-term supply agreement with Adaptimmune for CryoStor use in the SPEAR T Cell Platform.
  • Q2 and YTD 2017 Financial Highlights

  • Gross margin was 63% for the second quarter of 2017 compared to 56% in the second quarter of 2016. For the six months ended June 30, 2017, gross margin was 62% compared to 57% for the same period last year.
  • Operating expenses for the second quarter of 2017 totaled $1.9 million, a reduction of 28% compared to $2.7 million in the second quarter of 2016. For the six months ended June 30, 2017, operating expenses were $3.8 million, a reduction of 27% compared to $5.3 million for the same period last year.
  • Operating loss for the second quarter of 2017 was $341,000, compared to $1.6 million in the second quarter of 2016. For the six months ended June 30, 2017, the operating loss was $805,000, compared to $3.1 million for the same period last year.
  • Net loss attributable to BioLife for the second quarter of 2017 was $768,000, or $0.06 per share, compared to a net loss attributable to BioLife of $1.4 million, or $0.11 per share, in the second quarter of 2016. For the six months ended June 30, 2017, the net loss attributable to BioLife was $1.6 million, or $0.13 per share, compared to a net loss attributable to BioLife of $2.6 million, or $0.21 per share, for the same period last year.
  • Adjusted EBITDA for the second quarter of 2017 was positive $59,000, compared to negative $969,000 in the second quarter of 2016. For the six months ended June 30, 2017, adjusted EBITDA was positive $15,000 compared to negative $2.0 million for the same period last year.
  • On June 30, 2017, the outstanding $4.25 million in principal and accrued interest due to our largest shareholder, WAVI Holdings AG ("WAVI"), was converted into shares of non- convertible, redeemable Series A Preferred stock.
  • Roderick de Greef, Chief Financial Officer, remarked, "The positive trends in our financial and operating results continued across the board in the second quarter of 2017. The modification of our debt into shares of our Series A Preferred stock bolstered our shareholder's equity, and provides us with additional financial flexibility going forward. It is also noteworthy that we reached positive adjusted EBITDA in this quarter, which is earlier than we had originally anticipated."

    2017 GuidanceManagement reaffirms the full-year revenue guidance for biopreservation media products, which is expected to grow between 20 - 25% over 2016, with revenue for 2017 in excess of $10 million.

    Based on the financial results for the six months ended June 30th, 2017, management has revised the balance of our full-year 2017 guidance as follows:

  • Gross Margin for 2017 is now expected to be between 58% to 62%, which is up from the previously provided range of 55% to 60%.
  • Annual operating expenses are expected to be between $8 to $8.5 million, which is down from the previous range of $8 to $9 million.
  • Positive adjusted EBITDA is now expected for the full-year of 2017.
  • Conference Call & WebcastThe Company will host a conference call and live webcast at 4:30 p.m. EST this afternoon. To access the live webcast, please go to the BioLife Solutions website at, and click on the "Investors" tab, and scroll down to select the "Events" icon where you will be directed to the live webcast. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 65255951. A webcast replay will be available approximately two hours after the call and will be archived on for 90 days.

    About BioLife SolutionsThe Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.

    For more information please visit, and follow BioLife on Twitter.

    Cautions Regarding Forward Looking StatementsExcept for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, commercial manufacturing of our customers' products, and projected financial results, cash flow and liquidity, including the potential for reaching positive adjusted EBITDA for the full-year of 2017. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

    Discussion of Non-GAAP Financial MeasuresBioLife's management believes that the non-GAAP measure of "Adjusted EBITDA" enhances an investor's understanding of the Company's financial and operating performance and its future prospects by being more reflective of core operating performance. BioLife's management uses this financial metric for strategic decision making, forecasting future financial results, and evaluating current period financial and operating performance. The presentation of non-GAAP financial information is not intended to be reviewed in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. A reconciliation of GAAP to non-GAAP results is included in the financial tables in this press release.

    Adjusted EBITDA Definition:"Adjusted EBITDA" is a non-GAAP measure defined by BioLife as net income/(loss) excluding interest expense/(income), income tax expense, depreciation expense, amortization expense, stock-based compensation expense and the loss/(gain) on equity method investments.

    Media & Investor Relations Roderick de Greef Chief Financial Officer (425) 686-6002 BIOLIFE SOLUTIONS, INC.Unaudited Condensed Consolidated Statements of Operations (In thousands, except per share amounts)Three Months EndedSix Months EndedJune 30,2017June 30,2016June 30,2017June 30, 2016 Revenue





    3,842 Cost of product sales9578731,8851,644 Gross profit1,6011,1173,0392,198 Gross margin %63%56%62%57% Operating expenses Research and development3195996051,103 Sales and marketing5468491,0591,583 General and administrative1,0771,2632,1802,598 Total operating expenses1,9422,7113,8445,284 Operating loss(341)(1,594)(805)(3,086) Total other income (expenses)(427)(126)(834)(124)Net loss(768)(1,720)(1,639)(3,210)Net loss attributable to non-controlling interest––364––627Net loss attributable to BioLife Solutions, Inc.





    (2,583)Basic and diluted net loss per common share attributable to BioLife Solutions, Inc.





    (0.21)Basic and diluted weighted average common shares used to calculate net loss per common

    share13,10112,56813,03312,513Non-GAAP Reconciliation:Three Months EndedSix Months EndedJune 30, 2017June 30, 2016June 30, 2017June 30, 2016Net loss attributable to BioLife Solutions, Inc.





    (2,583)Interest expense/(income), net10581886Depreciation expense8792177184Amortization of debt discount623115631EBITDA(514)(1,225)(1,118)(2,362)Share-based compensation (non-cash)313256644403Loss from equity-method investment in SAVSU (non-cash)260––489––Adjusted EBITDA






    BIOLIFE SOLUTIONS, INC.Unaudited Condensed Consolidated Balance Sheet Information(In thousands)June 30,2017December 31,2016Cash and cash equivalents$

    2,315$1,406Accounts receivable1,1731,194Inventories1,7691,758Total current assets5,6794,628Total assets8,4827,927Total current liabilities1,0451,133Total liabilities1,6614,761Total Shareholders' equity6,8213,166

    BIOLIFE SOLUTIONS, INC.Unaudited Condensed Consolidated Statement of Cash Flows Information(In thousands)Six Months EndedJune 30, 2017June 30, 2016Cash provided/(used) by operating activities



    (2,775)Cash provided/(used) by investing activities (78)855Cash provided/(used) by financing activities1,2591,065Net increase (decrease) in cash and equivalents



    (855) View original content with multimedia:

    SOURCE BioLife Solutions, Inc.
    Copyright©2017 PR Newswire.
    All rights reserved

    Related biology technology :

    1. BioLife Solutions Announces License Agreement
    2. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
    3. BioLife Solutions Named One of Washingtons Best Companies
    4. BioLife Solutions Announces Strategic Partnership with HemaCare
    5. BioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013
    6. BioLife Solutions Expands Strategic Relationship with STEMCELL Technologies Inc.
    7. BioLife Solutions Preliminary 2013 Revenue Grows to $9 Million
    8. BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014
    9. BioLife Solutions Sets Date for Annual Meeting of Stockholders
    10. BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015
    11. BioLife Solutions Reports 1st Quarter 2015 Results
    Post Your Comments:
    (Date:9/17/2019)... , ... September 17, 2019 , ... Tucker, a Labrador ... only four months old, Tucker was limping and lame on his right hip and ... dysplasia and it was called “the worst case the vet had seen.” He was ...
    (Date:9/17/2019)... ... September 16, 2019 , ... ... with the China Focus @ Biotech Week Boston, a forum organized by MyBioGate, ... in healthcare innovation. , After a careful process of evaluation, twelve companies out ...
    (Date:9/9/2019)... ... September 09, 2019 , ... Visikol CEO Dr. Michael Johnson ... focused on how best to characterize 3D cell culture models. The inherent problem of ... too thick and opaque to image through and therefore traditional wide-field or even confocal ...
    (Date:8/29/2019)... ROCHESTER, N.Y. (PRWEB) , ... August 29, 2019 ... ... within a chronic disease affecting grapevines, a feat they hope will ultimately help ... products. , Researchers including several Rochester Institute of Technology faculty and alumni sequenced ...
    Breaking Biology Technology:
    (Date:8/27/2019)... ... August 26, 2019 , ... Shoreline Biome , ... strain level, has hired Bill McKenzie as its CEO and Karen Woodward as its ... Shoreline Biome meet growing demand for its products and expand the company’s sales worldwide. ...
    (Date:8/27/2019)... ... August 27, 2019 , ... Ambry Genetics ... improve genetic testing guidelines. In the largest cohort study of its kind, Ambry ... at-risk patients. , Clinicians use guidelines to inform decisions about which patients ...
    (Date:8/25/2019)... ... 2019 , ... Sierra Instruments is pleased to announce that their redesigned website ... live. Sierra has redesigned entry to the site with both engineers and those new ... to navigate with streamlined menus and simple access to resources and information on products ...
    Breaking Biology News(10 mins):